{"id":1099,"date":"2018-09-21T09:05:57","date_gmt":"2018-09-21T09:05:57","guid":{"rendered":"https:\/\/www.ipsen.com\/spain\/?p=1099"},"modified":"2024-12-17T08:14:32","modified_gmt":"2024-12-17T06:14:32","slug":"ipsen-recibe-la-opinion-positiva-del-chmp-para-el-uso-de-cabometyx-cabozantinib-para-el-tratamiento-en-segunda-linea-de-pacientes-con-carcinoma-hepatocelular-chc","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/spain\/press-releases\/ipsen-recibe-la-opinion-positiva-del-chmp-para-el-uso-de-cabometyx-cabozantinib-para-el-tratamiento-en-segunda-linea-de-pacientes-con-carcinoma-hepatocelular-chc\/","title":{"rendered":"Ipsen recibe la opini\u00f3n positiva del CHMP para el uso de Cabometyx\u00ae (cabozantinib) para el tratamiento en segunda l\u00ednea de pacientes con carcinoma hepatocelular (CHC)"},"content":{"rendered":"\n